#ES­MO22: Trodelvy's long-await­ed sur­vival da­ta in breast can­cer are fi­nal­ly in — and bet­ter than ex­pect­ed

It’s been weeks since Gilead tout­ed “clin­i­cal­ly mean­ing­ful” over­all sur­vival re­sults from a sec­ond in­ter­im analy­sis of Trodelvy in a sub­set of metasta­t­ic breast can­cer pa­tients. Now we fi­nal­ly have a look at the hard da­ta.

Pa­tients with HR+/HER2- metasta­t­ic breast can­cer who re­ceived Trodelvy af­ter pri­or en­docrine ther­a­py, CDK4/6 in­hibitors and two to four lines of chemo sur­vived a me­di­an of 14.4 months, as op­posed to just 11.2 months for those who re­ceived physi­cian’s choice chemother­a­py, Gilead an­nounced on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER